2007-12-03
The Wall Street Journal
Addex and Merck to Collaborate On Parkinson's Drug Development
ZURICH -- Addex Pharmaceuticals SA said Monday it entered an exclusive collaboration and license agreement with Merck & Co. to develop a new class of drugs for the treatment of Parkinson's disease -- and potentially others -- for up to $170.
2008-11-19
Cash
Interview Vincent Mutel, CEO Addex
Der Addex CEO sagt,wie die Verhandlugen mit neuen Partner laufen und wie lange die Cash-Reserven noch reichen.
2008-11-19
STOCKNEWS.ch
Addex: Implications of todays Novartis newsflow
The stock is seeing continued buying interest today based on several factors:
2008-11-19
AWP
Addex-Aktie nach Novartis-Update zu mGluR5-Inhibitor gefragt
Zürich (AWP) - Die Aktien der Addex Pharmaceuticals SA ziehen am Mittwoch weiter an.
2008-11-14
Genetic Engineering News
GPCR Market Exhibits Rapid Diversification
Technologic and Scientific Advances Spark Expansion of the Repertoire of GPCR-Targeted Drugs Ken Rubenstein, Ph.D. The differences in targets between launched and developmental compounds addressing GPCRs reflect a sea change in the pharmaceutical research...
2008-11-13
Bloomberg
Brainstorm at Roche Leads to New Valium-Like Drugs (Update2)
By Dermot Doherty Nov. 13 (Bloomberg) -- Vincent Mutel saw so much potential in a new way of tweaking the brain's circuitry that he left a job he'd had for 15 years to bet his future on a start...
2008-11-13
STOCKNEWS.ch
Addex: Outperformer In Times Of Financial Crisis And Recession?
The Addex approach represents a promising way for creating medicines at a time when the pharmaceutical industry is struggling to find new products.
2008-11-12
Reuters UK
Glaxo venture arm lifts Addex stake to 5 percent
(Reuters) - GlaxoSmithKline (GSK.L: Quote, Profile, Research) has increased its stake in Addex Pharmaceuticals (ADXN.S: Quote, Profile, Research) to 5 percent, the Swiss biotech firm said on...
2008-09-26
The Wall Street Journal
UPDATE: GSK Lifts Stake In Swiss Biotech Addex to 3%
Article Email Printer Friendly Share: Yahoo Buzz MySpace Digg Text Size By Hans Schoemaker Of DOW JONES NEWSWIRES ZURICH (Dow Jones)--Swiss biotechnology company Addex Pharmaceutical SA...
2008-09-13
Finanz Und Wirschaft
«Unternehmenswert wird steigen»
Addex-CEO Vincent Mutel verhandelt über Kooperation mit einem Pharinakonzern
2008-08-29
DOW JONES NEWSWIRES
FOCUS: Big Pharma Casts A Hungry Eye On Switzerland's Addex
Markets clamor for news about a deal with a big pharmaceutical player.
2008-08-22
RSR 1ERE
La chasse aux rachats dans le secteur des pharmas
Les grands laboratoires se sont lancés dans la course aux fusions-acquisitions avec des raids sur les entreprises de biotechnologies, massacrées en bourse et riches en molécules prometteuses. Interview de Vincent Mutel, patron du biotech genevois Addex.
2008-08-13
Agefi
Addex profite des retombées de l’acquisition de Speedel
La société genevoise a bondi de 9,3% à 45,90 francs hier suite à des rumeurs de rachat.
2008-08-12
Bloomberg
Addex Has Record Increase on Acquisition Speculation
Addex Pharmaceuticals Ltd., the Swiss biotechnology company working with Merck & Co., had a record rise in Zurich trading on speculation it is a takeover target.
2008-07-28
CASH.ch
CASH.ch interviews CEO after 1H08 Financial Results
CEO Vincent Mutel discusses the outlook for Addex with CASH.ch
2008-05-01
PharmaTelevision
Interview with Addex CEO, Vincent Mutel
Dr. Mutel discusses Addex products, strategy and technology
2008-03-03
MedNous
How Addex Pharmaceuticals secured two multi-million dollar deals with Merck
MedNous, a medical business journal, featured the deals with Merck & Co., Inc.
2008-02-27
Addex Pharmaceuticals
BioBusiness Conference (Jan 2008)
Merck & Co., Inc. and Addex jointly presented our two deals
2008-02-24
The New York Times
Daring to Think Differently About Schizophrenia
NORTH WALES, Pa. SCIENTISTS who develop drugs are familiar with disappointment brilliant theories that don’t pan out or promising compounds derailed by unexpected side effects.
2008-01-07
BioCentury
The difference between 4 and 5
In the space of a month, Addex Pharmaceuticals S.A. and Merck & Co. Inc. have done two deals that help benchmark the value of research-stage and preclinical assets.
2008-01-04
Wall Street Journal Template
Merck and Addex Reach Deal On Developing Schizophrenia Drug
LONDON -- Addex Pharmaceuticals and Merck & Co. reached a deal to develop a drug candidate for schizophrenia, under which the blue-chip drug giant will pay the Swiss firm up to $702 million in cash plus royalties, the companies announced Thursday.
2008-01-04
In Vivo Blog
Addex Ups Dealmaking Ante
Addex Pharma today took a step up the dealmaking ladder, partnering its pre-IND positive allosteric modulator ADX63365 and back-up compounds with Merck & Co.
2007-12-10
BioCentury
Modifying Parkinson's
Most drugs for Parkinson’s disease target dopamine, which provides short-term, palliative treatment but is accompanied by neurological side effects and eventually loses efficacy as patients develop tolerance.